Prurex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prurex

This section provides a clear, foundational overview of the medicine Prurex, focusing strictly on its identity, composition, and general purpose.

Property Description
Active ingredient Crotamiton (C₁₃H₁₇NO)
Form Cream or Lotion
Pharmacological class Scabicide and Antipruritic Agent
Common use Relief of itching and elimination of mites
Origin Synthetic compound

What Type of Medicine is Prurex and How is it Classified?

Prurex is a topical pharmaceutical preparation containing the sole active ingredient, Crotamiton (INN). This compound is classified as both a scabicide and an antipruritic agent, a designation that defines its core dual action. Crotamiton is utilized to address conditions associated with mite infestation and severe itching. The medicine is designed to help manage both the cause and the most bothersome symptom of the dermatological issue. Crotamiton is a synthetic compound that is delivered for localized dermal use as a single-entity product.

Active Ingredient and Topical Preparation Form

The active ingredient, Crotamiton, is formulated within an emulsified base to create the primary dosage forms of a cream or a lotion, both intended for topical (dermal) application. These preparations are specifically designed to concentrate the active substance at the site of irritation on the skin surface. Crotamiton is used for treating conditions involving pruritus and parasitic activity. This medicine helps ease discomfort by simultaneously eliminating the parasites and calming the nerve endings responsible for the persistent itch sensation.

General Purpose and Primary Benefit of Crotamiton

The central purpose of Prurex is derived directly from its pharmacological actions: to provide relief from intense itching (pruritus) while also addressing the microscopic arthropods that cause irritation. Its dual action is utilized to manage the two primary aspects of the condition: eliminating the parasitic mites, such as Sarcoptes scabiei, and providing rapid desensitization to reduce the patient's discomfort. A typical, neutral use scenario involves applying the preparation to areas experiencing generalized, persistent itching associated with parasitic infestation.

What side effects are possible with Prurex?

Possible side effects and safety information

The official safety profile for Prurex (Crotamiton) is structurally defined by its topical administration and primarily encompasses reactions affecting the skin. These adverse effects are classified in regulatory documents under Skin and subcutaneous tissue disorders, which is the system most commonly associated with reactions.

Key adverse reactions listed in official labeling include local primary irritation at the site of application, allergic sensitization, and paradoxically, the aggravation of itching (pruritus). Most localized reactions are categorized using standard frequency terminology, such as Uncommon or Rare.

Category Documented Safety Notes
Serious Adverse Reactions Rare possibility of severe hypersensitivity reactions (e.g., angioedema) or systemic toxicity following accidental oral ingestion or excessive absorption through compromised skin.
Safety Restrictions Contraindicated in cases of known hypersensitivity to Crotamiton or any component. Use is restricted on acutely inflamed, raw, or weeping skin (acute exudative dermatoses) to prevent increased systemic absorption.
Special Populations Regulatory documents note limited data for use during pregnancy (where it is used only if clearly necessary) and in the pediatric population.

Discontinuation of the product is officially recommended if signs of primary irritation or allergic sensitization appear. The regulatory framework emphasizes adherence to the contraindications related to skin integrity and known allergies, defining the essential limitations for the medicine's safe use.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

The regulatory overdose profile for Prurex (Crotamiton) is based on the risk of accidental oral ingestion or excessive systemic absorption through damaged skin.

Overdose presentations are documented to include primary effects on the central nervous system (CNS) and the gastrointestinal (GI) system.

Documented Manifestations Following oral ingestion, signs may include a burning sensation in the mouth and throat, irritation of mucosal surfaces, nausea, vomiting, and abdominal pain. More severe systemic exposure may lead to CNS effects such as convulsions and has been associated with the potential for shock and acute intoxication. For topical overuse, signs may be limited to local symptoms like severe skin irritation.

Immediate Help-Seeking Requirements Regulatory labeling mandates an immediate response if overdose or accidental ingestion is suspected. Emergency services must be contacted immediately for suspected acute intoxication or when oral ingestion has occurred, as this is classified as a toxic event requiring professional intervention in all cases.

Management and Treatment Overdose management is officially defined as symptomatic and supportive treatment. Procedures such as gastric lavage and the use of activated charcoal may be considered following ingestion. It is officially stated that no specific pharmacological antidote is known for Crotamiton overdose, necessitating hospital monitoring to manage severe symptoms.

Therapeutic Uses of Prurex

What Prurex Treats: Main Uses and Benefits

Prurex is a short-term supportive medication used for easing various forms of symptomatic distress. Managing acute, fluctuating symptoms is often part of supportive care. Its utility spans several clinical situations where temporary relief from burdensome symptoms is relevant to supporting daily comfort and functional stability.

Prurex is generally used for conditions involving episodic or fluctuating manifestations, applied in clinical settings that involve acute or unstable symptom patterns. It is applied in addressing symptom clusters that may become intense or disruptive, such as those related to physical discomfort, systemic imbalance, or heightened physiological activity.


Therapeutic Applications

The medicine is relevant for easing distressing symptoms in contexts where short-term symptom management is appropriate. It may assist with maintaining functional stability when symptoms create noticeable physiological strain. It provides supportive relief that may help patients cope more steadily with symptom fluctuations.

“Applied in scenarios where additional symptomatic support is needed.”

Quick Fact: Support for Symptom Clusters

Prurex is used in contexts marked by increased discomfort or tension, commonly for conditions presenting with acute episodes or those marked by increased physiological stress.

Regulatory References

  1. NIH MedlinePlus guidance on supportive symptom management

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Prurex (Crotamiton Topical) — Official Regulatory Information

This section outlines population eligibility rules strictly based on government-approved labeling.

Eligibility Classification Official Regulatory Status
Absolute Contraindications Use is prohibited for patients with a known hypersensitivity to Crotamiton or any component of the formulation, or those who manifest a primary irritation response to topical medicines.
Skin Condition Restriction The product must not be applied to skin that is acutely inflamed, raw, weeping, or oozing until the acute inflammation has resolved. Contact with the eyes, mouth, or mucous membranes is also prohibited.
Age-Group Eligibility Crotamiton is approved for use in adults. Safety and effectiveness in children have not been established by the FDA. Clinical studies did not include sufficient numbers of subjects aged 65 and older to determine differential responses in older adults.
Pregnancy and Lactation Assigned US FDA Pregnancy Category C; use during pregnancy is not recommended unless clearly needed. Use while breastfeeding is not recommended unless directed by a physician, and the drug should not be applied to the nipple area.

The official documents define who can and cannot use Crotamiton topical by establishing absolute contraindications based on allergic response and critical restrictions concerning the integrity of the application site. For patient groups like children, regulatory labeling indicates that safety and effectiveness have not been established, limiting eligibility to the adult population for standard use.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Prurex (Crotamiton)

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Other Topical Preparations and Potentially Irritating Agents applied to the skin.
Specific interacting medicines (if explicitly listed) None explicitly listed by name in official interaction sections.
Mechanistic basis of interactions (only if stated in label) Local Pharmacodynamic Interaction Risk (potential for additive dermal effects, such as irritation).
Timing-based interaction rules (if applicable) Application must be deferred if skin is acutely inflamed, raw, or weeping. Eczema should be managed before initiating treatment for scabies.
Population-specific interaction notes (if applicable) None documented.
Interaction-related restrictions Co-administration or consecutive use with other topical products that may cause local irritation should be avoided.

Interaction Classifications (High-Level)

Classification Official Regulatory Statement
Interaction severity classification (as defined in official documents) Not formally classified with a severity level; necessitates caution due to potential local irritation.
Regulatory basis FDA Drug Labeling Information and EMA/National Summary of Product Characteristics.
Interaction-context constraints (as defined in official documents) The primary constraint is based on the physical condition of the application site (e.g., presence of inflammation).

Resulting Interaction Structure

Official interaction statements:

  • Official regulatory labels do not document any specific systemic drug–drug interactions, including those mediated by metabolic enzymes or drug transporters.
  • The regulatory labels state there are no known interactions with food or drinks.
  • Crotamiton should not be applied concurrently or consecutively with other topical preparations that may cause additive local irritation.
  • There are no formal, systemic drug contraindications listed in the regulatory documents based on an interaction mechanism.
  • Application must be deferred if the skin is acutely inflamed, raw, or weeping.

Connection to the overall interaction profile

Official regulatory documents define the product’s interaction structure primarily by the absence of systemic pharmacokinetic interactions due to minimal systemic absorption. The only documented interaction pattern is a local pharmacodynamic effect, resulting in a necessary restriction against the co-administration of other potentially irritating topical products and a condition-based rule regarding the state of the skin at the site of application.

Mechanism of Action

The action of Prurex, containing the active ingredient Crotamiton, is defined by two complementary, independent mechanistic domains that target the functional dynamics of peripheral sensory neurons and the parasitic agent.


Modulation of Peripheral Sensory Nerve Signaling

This domain concerns the modulation of sensory signaling through a targeted pathway on the skin's sensory nerves. Crotamiton acts as an inhibitor of the Transient Receptor Potential Vanilloid 4 (TRPV4) ion channel, a critical molecular switch on peripheral sensory neurons . By blocking the influx of cations through this channel, the drug reduces the electrical excitability of the nerve ending, which dampens the physiological transmission of afferent sensory signals.


Direct Pathogen Toxicity and Functional Disruption

This domain describes the direct toxic effect exerted against the Sarcoptes scabiei mite. Crotamiton engages mechanisms that functionally disrupt the mite's vital processes, likely affecting its nervous system or key metabolic pathways. This resulting physiological change is the death and functional disruption of the parasitic mite.

Dosage and Administration Information

How Prurex is Used: Official Administration Guidelines

Prurex (Crotamiton) is administered via specific protocols. The official guidelines define distinct usage patterns for its dual functions, ensuring appropriate application for the intended purpose.


Administration Scope

Instruction Detail
Route of Administration Strictly Topical (Dermal) Use only. Application is restricted to the skin and is not approved for internal or mucosal use.
Official Dosage Forms Available as a 10% Cream or 10% Lotion preparation.
Preparation Requirements The skin must be cleaned and thoroughly dried before the initial application. The lotion form requires the container to be shaken well prior to use.

Frequency and Treatment Course

Use Pattern Course Detail
Scabicidal Use A two-day course requiring two full-body applications administered 24 hours apart. The first application is not washed off before the second is applied.
Antipruritic Use Applied topically to the affected area 2 to 3 times daily, or as needed for relief.

Special Procedural Rules

For the scabicidal course, the preparation must be applied to the entire surface of the body from the chin downwards, with careful attention to skin folds, creases, and between the fingers and toes. Post-treatment, the medication is removed via a cleansing bath 48 hours after the final application. In the pediatric population, usage in children under three years of age is limited to a maximum of once daily application under medical supervision.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prurex

This section summarizes the official research evidence for Prurex (Crotamiton), focusing on the types of studies that have been conducted and the findings they describe, according to regulatory and scientific sources. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.


Evidence for Use in Scabies Infestation

Research exploring Prurex for scabies infestation includes Randomized Controlled Trials (RCTs) and systematic reviews that examined Crotamiton alongside other standard agents studied in research contexts. Studies primarily focused on measuring the short-term outcomes, specifically the clinical cure rate (seeing the lesions resolve) and the parasitological cure rate (confirmed mite status). These trials primarily included adults and older children/adolescents diagnosed with non-crusted (classic) scabies. Regulatory summaries note that evidence quality varies across studies that included Crotamiton in comparative research scenarios.

Evidence for the Relief of Symptomatic Pruritus (Itching)

Prurex was studied for its application as an anti-itch (antipruritic) agent, particularly in research contexts involving fluctuating or unstable symptoms. The evidence includes Controlled Clinical Trials that examined the medicine's application for persistent itching of the skin. Studies explored patient-reported outcomes describing perceived discomfort, such as using scales to measure changes in itch intensity. The evidence contributes to understanding symptom patterns, consistent with Crotamiton's classification as an antipruritic agent by regulatory authorities, although the data are still emerging and often come from older studies.


What is Still Uncertain About the Research for Prurex

Long-term outcomes are not fully established for either indication, as research primarily focused on short-term symptom changes over defined intervals, typically up to four weeks. The results apply only to the populations studied in the trials, and data for certain groups remain insufficient, including for pregnant populations and for infants or very young children.

Key Studies & References Symptom Management (MedlinePlus Medical Encyclopedia)

Frequently Asked Questions (FAQ)

Common questions about Prurex (FAQ)


Q: How quickly can someone expect to see an effect from Prurex?

A: For its use as an anti-itch (antipruritic) agent, official product information indicates that the preparation has a described duration of action providing relief from irritation for approximately 6–10 hours after each application. When used for scabies, the official treatment protocol requires the medication to remain on the skin for up to 72 hours, with the final removal taking place 48 hours after the second application.

Q: Can Prurex be used long-term?

A: Regulatory guidelines define short-term courses for its use as a scabicide, typically involving a treatment period of 24 to 72 hours of application time. Furthermore, official research summaries note that long-term outcomes are not fully established for this medicine, as clinical trials focused primarily on short-term symptom changes over specific intervals.

Q: What happens if I miss a dose of Prurex?

A: Patient directions often advise using it as soon as it is remembered. However, if it is almost time for the next scheduled application, official patient directions generally instruct to use only the next scheduled dose and to avoid using double or extra doses.

Q: Is it common to feel tired or drowsy when taking Prurex?

A: Prurex is formulated as a topical medication that is applied directly to the skin, resulting in minimal systemic absorption into the body. Due to this characteristic, common systemic side effects such as tiredness or drowsiness are not typically listed in the core adverse reactions or warnings sections of the regulatory labels.

Q: What should I do if a side effect seems mild but doesn't go away?

A: Official safety documents recommend discontinuation of the product if signs of primary irritation (such as a rash, burning, or stinging) or signs of allergic sensitization appear. If any side effects persist or seem to worsen after discontinuing the product, seeking guidance from a healthcare professional is generally recommended.

Q: Will taking Prurex interfere with my birth control pills?

A: Regulatory labels state there are no documented specific systemic drug–drug interactions, including those mediated by metabolic enzymes or drug transporters, due to the minimal systemic absorption of the topical application.

Q: What if I drink alcohol while taking Prurex?

A: Because Prurex is a topical medication with minimal systemic absorption, official regulatory labels state there are no known interactions with food or drinks, including alcohol. The potential for systemic interactions is considered low.

Q: Can men and women use Prurex equally, or are there gender differences?

A: The official product indications, dosing instructions, and safety information do not distinguish treatment protocols or restrictions based on gender. Use of the medicine is determined by the skin condition and general eligibility criteria, and not by a person's sex.

Q: Are children allowed to use Prurex, according to official guidelines?

A: The US FDA label states that safety and effectiveness in children have not been established. However, some international documents acknowledge use in children and specify that for the pediatric population under three years of age, usage is limited to a maximum of once daily application and requires medical supervision.

Q: Does Prurex cause weight gain?

A: Due to its topical administration and minimal systemic absorption, the adverse reactions listed in regulatory documents are mainly restricted to local skin reactions at the application site. Systemic effects like weight gain are not listed as a common or expected side effect.

Q: Can Prurex be crushed or split if it's a tablet?

A: Prurex is an external, topical preparation that is only available as a cream or lotion and is not manufactured as an oral tablet. It is strictly for dermal application to the skin.

Q: What happens if I accidentally take two doses of Prurex?

A: The regulatory documents warn that the product is for external use only and may be harmful if swallowed. Official warnings recommend seeking medical attention if a large amount is ingested. For excessive topical use (topical 'overdose'), the main concern documented is the potential for increased local irritation at the application site.

Q: Does Prurex have any effect on mental clarity or mood?

A: As a topical drug with minimal systemic absorption, the medicine is not generally associated with effects on the Central Nervous System (CNS). Effects on mental clarity or mood are not listed among the common adverse reactions in the core regulatory documents.

Q: Is there any information on Prurex use in people with kidney issues?

A: Given the minimal systemic absorption of Crotamiton following topical application, official labeling typically does not include dosage adjustments or specific precautions for renal (kidney) impairment.

Q: Can Prurex be taken on an empty stomach?

A: Prurex is a topical cream or lotion applied to the skin and is not taken orally. Therefore, the state of the stomach (empty or full) is not relevant to its administration or function.

Q: Are there official reports of Prurex being misused?

A: While the official documentation does not contain dedicated sections on misuse, product labeling includes strong warnings for external use only and indicates potential harm if swallowed, addressing the most common risk of non-indicated use.

Q: Does Prurex contain any common allergens like gluten or lactose?

A: The active ingredient is Crotamiton. However, the presence of specific excipients (inactive ingredients) like gluten or lactose depends entirely on the specific manufacturer's formulation of the cream or lotion. This information must be checked directly on the full packaging or patient information leaflet (PIL).

Q: What are the official guidelines for stopping Prurex?

A: Official guidelines recommend stopping the use of Prurex 48 hours after the final scabicidal application, followed by a cleansing bath. It is also officially recommended to discontinue use if signs of severe local irritation or allergic sensitization occur.

Q: Does Prurex help with nerve pain, according to research?

A: Prurex is classified as an antipruritic (anti-itch) agent and works by modulating sensory nerve signaling to specifically reduce the sensation of itch. It is not formally indicated for the treatment of chronic neuropathic (nerve) pain; its indication is limited to pruritus and scabies.

Q: What is the official recommended age range for taking Prurex?

A: Use in the adult population is approved. However, the US FDA label states that safety and effectiveness in children have not been established. Some international documents do note a dosing limit for children under three years of age to be once daily and only under medical supervision.

Q: What is the maximum duration of use discussed in clinical trials for Prurex?

A: Clinical research for Prurex primarily focused on short-term symptom changes over defined intervals. This includes the scabies regimen, which is completed within 72 hours, and trials for antipruritic use, which typically spanned up to four weeks.

Q: Why is Prurex sometimes prescribed for conditions that aren't primarily about itch?

A: Prurex is officially indicated for two distinct, primary purposes: to treat scabies infestation by eliminating the mite, and for the relief of symptomatic pruritus (itching). The scabies indication is a parasitic condition, which may be the non-itch condition being referenced.

Q: Is Prurex safe for older adults?

A: Official documents state that clinical studies did not include sufficient numbers of subjects aged 65 years and older to determine if their responses are different than younger individuals. However, other reported clinical experience has not identified major differences in responses between elderly and younger patients, though greater sensitivity in some older individuals cannot be ruled out, and the potential benefits need to be considered when making decisions about use.

Q: Is Prurex safe to take during pregnancy, as described in official documents?

A: Prurex is classified as US FDA Pregnancy Category C. This classification indicates that the product should be given to a pregnant woman only if clearly needed. The potential benefits need to be considered when making decisions about use.

Q: How does Prurex compare to over-the-counter options, based on its official classification?

A: Prurex (Crotamiton) is classified as a Prescription Drug (Rx) in the United States and other regions. This regulatory classification means that its use requires a prescription from a licensed healthcare professional, which differentiates it from medicines sold without a prescription (over-the-counter, or OTC).

How should Prurex be stored and disposed of?

How to Store and Dispose of Prurex?

The storage and disposal instructions for Prurex (Crotamiton) are officially documented to maintain product stability and ensure user safety.

Storage Requirement Official Guidance
Temperature Store at Controlled Room Temperature (20 C to 25 C), protected from excessive heat.
Handling Keep from freezing and store away from direct light and moisture.
Packaging Keep the product in its original container and ensure it is tightly closed.
Safety Keep out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired Prurex, use an official drug take-back program or discard it in the household trash after mixing it with an undesirable substance like dirt or coffee grounds and sealing it in a plastic bag. Regulatory guidance advises against flushing the topical product, and mandates that environmental contamination, such as disposal into drains or surface water, be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prurex found in:

A-Z Index: